Table 2.
Multivariable analysis of drug discontinuation
| HR | 95% CI | P values | |
| TCZ-IV | – | – | – |
| TCZ-SC | 0.93 | 0.80 to 1.09 | 0.37 |
| Age, years | 1.00 | 1.00 to 1.00 | 0.85 |
| Female gender | 0.96 | 0.84 to 1.09 | 0.54 |
| Disease duration, years | 1.00 | 1.00 to 1.01 | 0.32 |
| Seropositivity | 0.89 | 0.77 to 1.03 | 0.12 |
| BMI | 1.01 | 1.00 to 1.02 | 0.22 |
| Ever smoking | 1.11 | 0.97 to 1.28 | 0.14 |
| Glucocorticoids | 1.16 | 1.03 to 1.31 | 0.02 |
| Concomitant csDMARD (base=none) | 0.88 | 0.78 to 0.98 | 0.03 |
| Any csDMARD MTX | 0.87 | 0.76 to 1.00 | 0.04 |
| MTX+other csDMARDs | 0.79 | 0.66 to 0.94 | 0.008 |
| Other than MTX | 0.97 | 0.84 to 1.12 | 0.67 |
| Previous bDMARDs (base=none) | |||
| 1 | 1.06 | 0.94 to 1.20 | 0.37 |
| 2 | 1.10 | 0.94 to 1.29 | 0.25 |
| ≥3 | 1.10 | 0.88 to 1.38 | 0.39 |
| CDAI at baseline | 1.01 | 1.00 to 1.02 | 0.001 |
| HAQ at baseline | 1.14 | 1.04 to 1.26 | 0.008 |
| ESR | 1.00 | 1.00 to 1.00 | 0.53 |
| Comorbidities | 0.99 | 0.87 to 1.13 | 0.87 |
bDMARD, biological disease-modifying antirheumatic drug; BMI, Body Mass Index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; TCZ-IV, intravenous tocilizumab; TCZ-SC, subcutaneous tocilizumab.